Clinical Trials Logo

Retinopathy of Prematurity (ROP) clinical trials

View clinical trials related to Retinopathy of Prematurity (ROP).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04004208 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

FIREFLEYE
Start date: September 25, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.

NCT ID: NCT02640664 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Rainbow Extension Study

RainbowExt
Start date: June 16, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)

NCT ID: NCT02386839 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

PEDAL
Start date: March 26, 2015
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).

NCT ID: NCT02134457 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity

CARE-ROP
Start date: August 2014
Phase: Phase 2
Study type: Interventional

This study is designed as an exploratory study to assess safety and efficacy of two different doses of the anti-VEGF agent ranibizumab (0.12 mg vs. 0.20 mg) in the treatment of infants with retinopathy of prematurity. Furthermore it shall help to improve safety in the treatment of ROP and provide explorative data on long-term effects of ranibizumab after intravitreal injection in neonates. The primary objective is to assess clinical efficacy of ranibizumab in children with ROP

NCT ID: NCT01096784 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

Start date: June 18, 2010
Phase: Phase 2
Study type: Interventional

To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for gestational age at birth while confirming the dose of rhIGF-1/rhIGFBP-3 is safe and efficacious.

NCT ID: NCT01054027 Completed - Clinical trials for Retinopathy of Prematurity (ROP)

Study on Effective Mydriasis in Premature Infants

Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the dilating effect of 0, 1, 2 or 3 drops of mydriatic (pupil dilating) in premature infants undergoing routine retinal (eye) screening exams for Retinopathy of Prematurity (ROP).